Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to 2.7.

  • Karyopharm Therapeutics' Equity Ratio fell 13881.48% to 2.7 in Q4 2025 from the same period last year, while for Dec 2025 it was 2.7, marking a year-over-year decrease of 13881.48%. This contributed to the annual value of 2.7 for FY2025, which is 13881.48% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Equity Ratio of 2.7 as of Q4 2025, which was down 13881.48% from 2.8 recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Equity Ratio peaked at 0.05 during Q4 2022, and registered a low of 2.8 during Q3 2025.
  • For the 5-year period, Karyopharm Therapeutics' Equity Ratio averaged around 0.84, with its median value being 0.53 (2021).
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 8218.02% in 2022, then crashed by 111818.73% in 2023.
  • Karyopharm Therapeutics' Equity Ratio (Quarter) stood at 0.26 in 2021, then skyrocketed by 82.18% to 0.05 in 2022, then tumbled by 1118.19% to 0.57 in 2023, then plummeted by 99.71% to 1.13 in 2024, then crashed by 138.81% to 2.7 in 2025.
  • Its Equity Ratio stands at 2.7 for Q4 2025, versus 2.8 for Q3 2025 and 2.28 for Q2 2025.